Literature DB >> 2852081

Flow cytometric and morphologic studies of HNK1+ (Leu 7+) lymphocytes in relation to cytomegalovirus carrier status.

J W Gratama1, H C Kluin-Nelemans, R A Langelaar, G J den Ottolander, T Stijnen, J D'Amaro, R Torensma, H J Tanke.   

Abstract

CMV carrier status of healthy individuals causes a persistent increase in the numbers of lymphocytes expressing the HNK1 (Leu 7) antigen. We investigated this phenomenon by correlating HNK1 fluorescence intensity of the CD3+, CD4+, CD8+ and CD16+ lymphocytes with their morphology. The study was performed on 112 healthy individuals as a function of their CMV carrier status. To this end, the CD3+, CD4+, CD8+ and CD16+ lymphocytes were stratified into subsets with undetectable (-), weak (+) and strong (++) levels of HNK1 fluorescence intensity, as well as into subsets with low, intermediate or high perpendicular light scatter (PLS) signals. Among the CD3+, CD4+ and CD8+ lymphocytes. CMV carrier status was associated with significantly increased numbers of HNK1(+) and particularly HNK1(++) cells. Among the CD16+ lymphocytes, CMV carrier status increased only the HNK1(++) ones significantly. There were clear positive correlations between the PLS characteristics of the CD3+, CD4+, CD8+ and CD16+ lymphocytes and their HNK1 fluorescence intensity. Microscopic analysis of CD3+ lymphocytes sorted into HNK1(-), HNK1(+) and HNK1(++) fractions revealed that the percentage of those cells containing azurophilic granules and the numbers of such granules per cell increased in proportion to their HNK1 fluorescence intensity. Thus, CMV also interacts with the HNK1+ lymphocytes of its healthy carriers by increasing the level of expression of that antigen which is accompanied by increased granularity. Those granular lymphocytes may include cytotoxic cells which are involved in the control of viral replication.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852081      PMCID: PMC1541784     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells.

Authors:  L K Borysiewicz; B Rodgers; S Morris; S Graham; J G Sissons
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

2.  Cell classification by laser light scattering: identification and separation of unstained leukocytes.

Authors:  G C Salzman; J M Crowell; J C Martin; T T Trujillo; A Romero; P F Mullaney; P M LaBauve
Journal:  Acta Cytol       Date:  1975 Jul-Aug       Impact factor: 2.319

3.  Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay.

Authors:  J M Middeldorp; J Jongsma; A ter Haar; J Schirm; T H The
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

4.  Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies.

Authors:  A W Ritchie; I Oswald; H S Micklem; J E Boyd; R A Elton; E Jazwinska; K James
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-04

5.  Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults.

Authors:  T Abo; C A Miller; C M Balch
Journal:  Eur J Immunol       Date:  1984-07       Impact factor: 5.532

6.  Frequency and specificity of varicella zoster virus IgM response.

Authors:  V A Sundqvist
Journal:  J Virol Methods       Date:  1982-11       Impact factor: 2.014

7.  Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for in vitro generation and specificity.

Authors:  L K Borysiewicz; S Morris; J D Page; J G Sissons
Journal:  Eur J Immunol       Date:  1983-10       Impact factor: 5.532

8.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens.

Authors:  L L Lanier; A M Le; J H Phillips; N L Warner; G F Babcock
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

9.  Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity.

Authors:  L K Borysiewicz; S Graham; J K Hickling; P D Mason; J G Sissons
Journal:  Eur J Immunol       Date:  1988-02       Impact factor: 5.532

10.  Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody.

Authors:  T Abo; M D Cooper; C M Balch
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

View more
  14 in total

1.  CD8 lymphocytosis in primary cytomegalovirus (CMV) infection of allograft recipients: expansion of an uncommon CD8+ CD57- subset and its progressive replacement by CD8+ CD57+ T cells.

Authors:  M Labalette; F Salez; F R Pruvot; C Noel; J P Dessaint
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

2.  Phenotypic study of CD4+ and CD8+ lymphocyte subsets in relation to cytomegalovirus carrier status and its correlate with pokeweed mitogen-induced B lymphocyte differentiation.

Authors:  J W Gratama; R A Langelaar; M A Oosterveer; J A van der Linden; A den Ouden-Noordermeer; A M Naipal; J W Visser; G C de Gast; H J Tanke
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

3.  Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population.

Authors:  M P Weekes; M R Wills; K Mynard; R Hicks; J G Sissons; A J Carmichael
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

4.  Relation between the increase of circulating CD3+ CD57+ lymphocytes and T cell dysfunction in recipients of bone marrow transplantation.

Authors:  M Izquierdo; M A Balboa; J M Fernández-Rañada; A Figuera; A Torres; A Iriondo; M López-Botet
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

5.  T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.

Authors:  M Levacher; S Tallet; M C Dazza; E Dournon; B Rouveix; J J Pocidalo
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

6.  Subsets of CD8+, CD57+ cells in normal, healthy individuals: correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses.

Authors:  E C Wang; J Taylor-Wiedeman; P Perera; J Fisher; L K Borysiewicz
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

7.  The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value.

Authors:  M Levacher; F Hulstaert; S Tallet; S Ullery; J J Pocidalo; B A Bach
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

8.  Cytomegalovirus-seropositive children show inhibition of in vitro EBV infection that is associated with CD8+CD57+ T cell enrichment and IFN-γ.

Authors:  Ebba Sohlberg; Shanie Saghafian-Hedengren; Eahsan Rasul; Giovanna Marchini; Caroline Nilsson; Eva Klein; Noémi Nagy; Eva Sverremark-Ekström
Journal:  J Immunol       Date:  2013-10-18       Impact factor: 5.422

9.  Differences in activation and tissue homing markers of natural killer cell subsets during acute dengue infection.

Authors:  Rassamon Keawvichit; Ladawan Khowawisetsut; Sakaorat Lertjuthaporn; Kanchana Tangnararatchakit; Nopporn Apiwattanakul; Sutee Yoksan; Ampaiwan Chuansumrit; Kulkanya Chokephaibulkit; Aftab A Ansari; Nattawat Onlamoon; Kovit Pattanapanyasat
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

10.  Impaired NK Cell Responses to Pertussis and H1N1 Influenza Vaccine Antigens in Human Cytomegalovirus-Infected Individuals.

Authors:  Carolyn M Nielsen; Matthew J White; Christian Bottomley; Chiara Lusa; Ana Rodríguez-Galán; Scarlett E G Turner; Martin R Goodier; Eleanor M Riley
Journal:  J Immunol       Date:  2015-04-08       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.